Competing interests
Chiari, ’
CHIARI
Luigi Celio has received consulting fees from Italfarmaco SpA, and Kyowa Kirin; speaker’s fee from Berlin-Chemie AG, and Helsinn. Diego Cortinovis has received speaker’s bureau and scientific advisor fees from Roche, AstraZeneca, BMS, MSD, Boehringer, Amgen, Novartis, and Lilly. Federica Bertolini has received speaker’s fee from MSD, AstraZeneca, and BMS; advisory board fees from MSD, Eli-Lilly, and Sanofi. Rita Chiari has declared speaker's fee - advisory boards from Astrazeneca, Roche, BMS, MSD, Pfizer, and Takeda. Erminio Bonizzoni received consulting fees from Helsinn. Sara Pilotto has received fees for consulting, advisory role and lectures from AstraZeneca, BMS, Boehringer, Eli-Lilly, Merck, Novartis, Roche, Amgen, Takeda. Emilio Bria received speakers’ and travels’ fees from MSD, AstraZeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis and Roche, as well as institutional research grants from AstraZeneca and Roche. All remaining authors have declared no conflicts of interest.